For several years, the interest of our research group focused on the synthesis and coordination properties of the neutral water-soluble aminophosphine PTA (1,3,5-triaza-7-phosphadamantane, Figure 1 left) and its derivatives. In our laboratories, some PTA transition metal complexes were successfully employed as catalysts for water-phase hydrogenations and hydroformylations, and their use as anticancer agents in medicinal inorganic chemistry was also demonstrated. Recently, a higher homologue of PTA, namely ligand 1,4,7-triaza-9-phosphatricyclo[5.3.2.1]tridecane (CAP, Figure 1 right), was reported in the literature. With the aim of exploring its coordination ability and properties, we obtained and characterized three novel ruthenium(II)-arene half-sandwich complexes bearing CAP as monodentate ligand. The new Ru(II)-CAP complexes (RACAP) showed modest activity in homogenous C=C bond catalytic reduction tests. On the other hand, when tested in vitro against selected cancer cell lines, they revealed higher activity than the corresponding well-known PTA analogues (RAPTA), still exhibiting a reasonable degree of cancer cell selectivity.
A step forward from PTA: Ru-arene complexes of CAP ligand as promising in vitro anticancer agents
Antonella Guerriero;Werner Oberhauser;Maurizio Peruzzini;Luca Gonsalvi
2017
Abstract
For several years, the interest of our research group focused on the synthesis and coordination properties of the neutral water-soluble aminophosphine PTA (1,3,5-triaza-7-phosphadamantane, Figure 1 left) and its derivatives. In our laboratories, some PTA transition metal complexes were successfully employed as catalysts for water-phase hydrogenations and hydroformylations, and their use as anticancer agents in medicinal inorganic chemistry was also demonstrated. Recently, a higher homologue of PTA, namely ligand 1,4,7-triaza-9-phosphatricyclo[5.3.2.1]tridecane (CAP, Figure 1 right), was reported in the literature. With the aim of exploring its coordination ability and properties, we obtained and characterized three novel ruthenium(II)-arene half-sandwich complexes bearing CAP as monodentate ligand. The new Ru(II)-CAP complexes (RACAP) showed modest activity in homogenous C=C bond catalytic reduction tests. On the other hand, when tested in vitro against selected cancer cell lines, they revealed higher activity than the corresponding well-known PTA analogues (RAPTA), still exhibiting a reasonable degree of cancer cell selectivity.File | Dimensione | Formato | |
---|---|---|---|
prod_389797-doc_134394.docx
solo utenti autorizzati
Descrizione: A step forward from PTA: Ru-arene complexes of CAP ligand as promising in vitro anticancer agents
Tipologia:
Versione Editoriale (PDF)
Dimensione
34.34 kB
Formato
Microsoft Word XML
|
34.34 kB | Microsoft Word XML | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.